Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema.
Ophthalmol Retina · 2025-Jul · PMID 39914485
First CST < 280 µm
Figure 4. Cumulative incidence of ( A ) first absence of IRF and ( B ) first presence of CST <280 μm over 100 weeks. Summaries of time to first absence of diabetic macular edema are Kaplan–Meier estimates, with the time variable defined as the target visit week. P values are nominal and not adjusted for multiplicity; no formal statistical conclusion should be made based on the P values. Statistics for pairwise comparisons were calculated using a separate model for each comparison. HRs were estimated by Cox regression. a The number of injections includes any active drug administered (faricimab or aflibercept), including medication errors. b Results from stratified analyses are presented for HR and log-rank test versus aflibercept. An HR >1 favors faricimab over aflibercept. c CST was measured as the distance between the internal limiting membrane and Bruch membrane. CI = confidence interval; CST = central subfield thickness; HR = hazard ratio; IRF = intraretinal fluid; Q8W = every 8 weeks; SRF = subretinal fluid; T&E = treat-and-extend.
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 3 | 2026-07-23T18:05:45+00:00 |